Trifexis is a monthly preventative for heartworm disease, kills fleas and treats and controls adult hookworms, roundworms and whipworms in dogs and puppies 8 weeks of age or older and 5 lbs of body weight or greater.
Trifexis protects your dog from:
TRIFEXIS (spinosad and milbemycin oxime) is available in five sizes for oral administration to dogs and puppies according to their weight. Each chewable flavored tablet is formulated to provide a minimum spinosad dose of 13.5 mg/lb (30 mg/kg) and a minimum milbemycin oxime dose of 0.2 mg/lb (0.5 mg/kg).
Dosage and Administration:
TRIFEXIS is given orally, once a month at the minimum dosage of 13.5 mg/lb (30 mg/kg) spinosad and 0.2 mg/lb (0.5 mg/kg) milbemycin oxime body weight. For heartworm prevention, give once monthly for at least 3 months after exposure to mosquitoes.
Dosage Schedule:
Body Weight / Tablets Admininstered
5 to 10 lbs . . . One Tablet (Pink Box)
10.1 to 20 lbs . . . One Tablet (Orange Box)
20.1 to 40 lbs . . . One Tablet (Green Box)
40.1 to 60 lbs . . . One Tablet (Blue Box)
60.1 to 120 lbs . . . One Tablet (Brown Box)
Over 120 lbs . . . Administer the appropriate combination of tablets
Administer TRIFEXIS with food for maximum effectiveness. If a dose is missed and a monthly interval between doses is exceeded, then immediate administration of TRIFEXIS with food and resumption of monthly dosing will minimize the opportunity for the development of adult heartworm infections and flea reinfestations. If vomiting occurs within an hour of administration, redose with another full dose.
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian
Heartworm Prevention:
TRIFEXIS should be administered at monthly intervals beginning within 1 month of the dog's first seasonal exposure and continuing until at least 3 months after the dog's last seasonal exposure to mosquitoes. TRIFEXIS may be administered year round without interruption. When replacing another heartworm preventative product, the first dose of TRIFEXIS should be given within a month of the last dose of the former medication.
Flea Treatment and Prevention:
Treatment with TRIFEXIS may begin at any time of the year, preferably starting one month before fleas become active and continuing monthly through the end of flea season. In areas where fleas are common year-round, monthly treatment with TRIFEXIS should continue the entire year without interruption.
To minimize the likelihood of flea reinfestation, it is important to treat all animals within a household with an approved flea protection product.
Intestinal Nematode Treatment and Control:
TRIFEXIS also provides treatment and control of roundworms (T. canis, T. leonina), hookworms (A. caninum) and whipworms (T. vulpis). Dogs may be exposed to and can become infected with roundworms, whipworms and hookworms throughout the year, regardless of season or climate. Clients should be advised of measures to be taken to prevent reinfection with intestinal parasites.
Contraindications:
There are no known contraindications to the use of TRIFEXIS.
Warnings:
Not for human use. Keep this and all drugs out of the reach of children. Serious adverse reactions have been reported following concomitant extra-label use of ivermectin with spinosad alone, a component of TRIFEXIS.
Precautions:
Treatment with fewer than 3 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention.
Prior to administration of TRIFEXIS, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. TRIFEXIS is not effective against adult D. immitis. While the number of circulating microfilariae may decrease following treatment, TRIFEXIS is not indicated for microfilariae clearance.
Mild, transient hypersensitivity reactions manifested as labored respiration, vomiting, salivation and lethargy, have been noted in some dogs treated with milbemycin oxime carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae.
Use with caution in breeding females. The safe use of TRIFEXIS in breeding males has not been evaluated.
Use with caution in dogs with pre-existing epilepsy.
Puppies less than 14 weeks of age may experience a higher rate of vomiting.
Adverse Reactions: Few cases have been reported of vomiting, puruitis, lethargy, diarrhea, dermatitis, skin reddening, decreased appetite, pennal reddening
Storage: Store at 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F).
How Supplied:
TRIFEXIS is available in five tablet sizes. Each tablet size is available in color-coded packages of 6 tablets.
5-10 lbs (140 mg spinosad and 2.3 mg milbemycin oxime)
10.1-20 lbs (270 mg spinosad and 4.5 mg milbemycin oxime)
20.1-40 lbs (560 mg spinosad and 9.3 mg milbemycin oxime)
40.1-60 lbs (810 mg spinosad and 13.5 mg milbemycin oxime)
60.1-120 lbs (1620 mg spinosad and 27 mg milbemycin oxime)
Additional information not available for this medicine.